person · Reporting owner
Gottesdiener Keith Michael
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | Director · See Remarks | May 08, 2025 | May 12, 2025 |
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Director · CEO & President | March 09, 2020 | March 11, 2020 |
| Septerna, Inc.SEPN · Entity 2452 | Director | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.32 · Expires 2034-02-25 | Direct | 300,000 |
Reported balance
After 2025-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 100,000 · Balance 300,000 F1: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares.
RHYTHM PHARMACEUTICALS, INC.
Report date March 09, 2020 · Filed March 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 558,250 |
Reported balance
After 2020-03-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-03-09 · Exercise / conversion · Acquired 3,408 · Balance 558,250 F1: Includes 559 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on March 2, 2020. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.14 · Expires 2027-04-04 | Direct | 207,877 |
Reported balance
After 2020-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-09 · Exercise / conversion · Disposed 3,408 · Balance 207,877 F2: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 559 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on March 2, 2020.
F2: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017.
Septerna, Inc.
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.34 · Expires 2036-06-25 | Direct | 11,260 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 11,260 · Balance 11,260 F1: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 24,719 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 3,196 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 23:00 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 11,260 | $0.00 Strike: $37.34 | $0.00 |
DisclosureSEC source: 0001193125-26-291052 · ownership.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,260 Underlying: Common Stock · 11,260 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:59 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 33,246 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001193125-25-223384 · ownership.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,246 Underlying: Common Stock · 33,246 shares Expires 2035-09-24 F1 · derivative.exercise_date: 1/36th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments on each monthly anniversary of September 25, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:50 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001894562-25-000019 · wk-form4_1747082995.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-25 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest upon the achievement of certain performance milestones. On May 8, 2025, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved, resulting in the vesting of 100,000 shares. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 21:15 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 500,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001894562-25-000014 · wk-form4_1741122898.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2035-02-28 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 28, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 05, 2024 Filed Dec 9, 2024 23:23 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001894562-24-000049 · wk-form4_1733786581.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-25 F1 · derivative.exercise_date: Represents an option initially granted to the Reporting Person on February 25, 2024, a portion of which shares underlying this option shall vest on February 25, 2025 upon the achievement of certain performance milestones. On December 5, 2024, the board of directors of the Issuer determined that one of the performance milestone conditions was achieved. As a result, the shares underlying this option shall vest on February 25, 2025, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:29 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 226,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-24-000043 · wk-form4_1728592144.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 682,259 F1 · shares: On October 8, 2024, for bona fide estate planning purposes, the Reporting Person's spouse transferred 226,925 shares of Issuer common stock to a family trust for no consideration. F2 · ownership.nature: Shares held by a trust for which certain of the Reporting Person's family member is a trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| October 08, 2024 Filed Oct 10, 2024 20:29 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 226,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-24-000043 · wk-form4_1728592144.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 50,241 F1 · shares: On October 8, 2024, for bona fide estate planning purposes, the Reporting Person's spouse transferred 226,925 shares of Issuer common stock to a family trust for no consideration. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:18 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-24-000026 · wk-form4_1717791477.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 277,166 F1 · shares: On June 5, 2024, for bona fide estate planning purposes, the Reporting Person transferred 250,000 shares of Issuer common stock to his spouse for no consideration. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:18 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-24-000026 · wk-form4_1717791477.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,310,837 F1 · shares: On June 5, 2024, for bona fide estate planning purposes, the Reporting Person transferred 250,000 shares of Issuer common stock to his spouse for no consideration. Read SEC document |
| February 25, 2024 Filed Feb 27, 2024 14:35 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $8.32 | $0.00 |
DisclosureSEC source: 0001894562-24-000016 · wk-form4_1709044527.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2034-02-25 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of February 25, 2024, subject to the Reporting Person's continued service on each such vesting date. Not reported herein are performance-based options awarded to the Reporting Person on the same transaction date, which vest upon the achievement of certain performance criteria. As of the transaction date, the performance criteria for such performance-based options have not yet been satisfied. Read SEC document |
| November 11, 2023 Filed Nov 15, 2023 01:11 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-23-000034 · wk-form4_1700010693.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Indirect · By Spouse Disclosed balance after: 27,166 F2 · shares: On November 11, 2023, the Reporting Person's spouse transferred 5,000 shares of Issuer common stock to the Coolidge GST Trust-2022 for no consideration. Read SEC document |
| November 11, 2023 Filed Nov 15, 2023 01:11 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001894562-23-000034 · wk-form4_1700010693.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,560,837 F1 · shares: On November 11, 2023, the Reporting Person transferred 7,500 shares of Issuer common stock to the Gottesdiener Family GST Trust for no consideration. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,966 | Not disclosed Strike: $72.74 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 10 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,966 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,174 | Not disclosed Strike: $82.25 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 9 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,174 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,748 | Not disclosed Strike: $85.12 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 8 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,748 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,036 | Not disclosed Strike: $122.01 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 7 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,036 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 3,196 | Not disclosed Strike: $145.22 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 6 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,196 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,547 | Not disclosed Strike: $9.17 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 5 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,547 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,790 | Not disclosed Strike: $16.82 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 4 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,790 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,089 | Not disclosed Strike: $17.08 | Not disclosed |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · derivative · entry 3 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,089 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerCommon Stock | 8,111 | $19.00 | $154,109.00 |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:43 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | OtherCommon Stock | 24,719 | $19.00 | $469,661.00 |
DisclosureSEC source: 0001104659-23-117102 · tm2330435-9_4seq1.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,547 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001104659-23-064844 · tm2317083-7_4seq1.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,547 Underlying: Common Stock · 12,547 shares Expires 2033-05-24 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 8,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064844 · tm2317083-7_4seq1.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,830 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| March 31, 2023 Filed Apr 5, 2023 00:22 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 497,738 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001894562-23-000003 · wf-form4_168065415301251.xml · derivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 497,738 Underlying: Common Stock · 497,738 shares Expires 2033-03-31 F1 · derivative.exercise_date: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 31, 2023, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:16 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,790 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001104659-22-065902 · tm2217184-2_4seq1.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,790 Underlying: Common Stock · 12,790 shares Expires 2032-05-25 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:16 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-065902 · tm2217184-2_4seq1.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,719 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,089 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001104659-21-075219 · tm2118118-6_4seq1.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,089 Underlying: Common Stock · 12,089 shares Expires 2031-05-27 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:02 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-075219 · tm2118118-6_4seq1.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,982 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,966 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0001104659-20-068535 · tm2021501d6_4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 Underlying: Common Stock · 2,966 shares Expires 2030-05-28 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:04 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-068535 · tm2021501d6_4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,953 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,408 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001104659-20-031918 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,877 Underlying: Common Stock · 3,408 shares Expires 2027-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 20:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,408 | $6.14 | $20,925.12 |
DisclosureSEC source: 0001104659-20-031918 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 558,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 559 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on March 2, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,816 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001104659-20-019193 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,286 Underlying: Common Stock · 6,816 shares Expires 2027-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from January 6, 2017. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:00 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,816 | $6.14 | $41,850.24 |
DisclosureSEC source: 0001104659-20-019193 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 553 shares acquired under the issuer's 2017 Employee stock purchase plan on September 3, 2019. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 33,072 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-20-003024 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,208 Underlying: Common Stock · 33,072 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 33,072 | $4.59 | $151,800.48 |
DisclosureSEC source: 0001104659-20-003024 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 20:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-19-040756 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,280 Underlying: Common Stock · 7,500 shares Expires 2025-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options vest and become exercisable in 48 successive, equal monthly installments measured from August 3, 2015. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 20:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,500 | $4.59 | $34,425.00 |
DisclosureSEC source: 0001104659-19-040756 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,174 | $0.00 Strike: $82.25 | $0.00 |
DisclosureSEC source: 0001144204-19-031957 · tv524023_4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2029-06-20 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031957 · tv524023_4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,358 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| March 18, 2019 Filed Mar 19, 2019 20:25 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,329 | $30.27 | $70,498.83 |
DisclosureSEC source: 0001104659-19-015985 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,342 F3 · kind: On March 18, 2019, Mr. Gottesdiener sold 2,329 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $30.09 to $30.50, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 20:25 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,961 | $30.04 | $239,148.44 |
DisclosureSEC source: 0001104659-19-015985 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 508,671 F1 · kind: On March 15, 2019, Mr. Gottesdiener sold 7,961 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 20:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,506 | $30.05 | $45,255.30 |
DisclosureSEC source: 0001104659-19-015281 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 516,632 F4 · kind: On March 14, 2019, Mr. Gottesdiener sold 1,506 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.50, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 20:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,782 | $30.06 | $233,926.92 |
DisclosureSEC source: 0001104659-19-015281 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,138 F1 · kind: On March 13, 2019, Mr. Gottesdiener sold 7,782 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 303 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on February 28, 2019. Read SEC document |
| February 27, 2019 Filed Feb 28, 2019 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,814 | $30.01 | $54,438.14 |
DisclosureSEC source: 0001104659-19-011530 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525,617 F3 · kind: On February 27, 2019, Mr. Gottesdiener sold 1,814 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.09, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 635 | $30.13 | $19,132.55 |
DisclosureSEC source: 0001104659-19-011530 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,431 F1 · kind: On February 26, 2019, Mr. Gottesdiener sold 635 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.01 to $30.14, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 918 | $30.05 | $27,585.90 |
DisclosureSEC source: 0001104659-19-009555 · a4.xml · nonDerivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,066 F3 · kind: On February 19, 2019, Mr. Gottesdiener sold 918 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 12,002 | $30.02 | $360,300.04 |
DisclosureSEC source: 0001104659-19-009555 · a4.xml · nonDerivative · entry 1 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,984 F1 · kind: On February 15, 2019, Mr. Gottesdiener sold 12,002 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.18, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 13, 2019 Filed Feb 15, 2019 21:09 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $29.78 | $0.00 |
DisclosureSEC source: 0001104659-19-009043 · a4.xml · derivative · entry 2 Gottesdiener Keith Michael · CIK 0001615856 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2029-02-12 F3 · derivative.exercise_date: This option was granted on February 13, 2019 and the shares underlying this option vest in sixteen equal quarterly installments beginning on May 13, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.